Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline [Yahoo! Finance]
Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]
Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.
Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.